Why the study?
Does XV454 improve inhibition of platelet aggregation compared to abciximab in flow models of thrombosis?
Does XV454 improve inhibition of platelet aggregation compared to abciximab in flow models of thrombosis?
XV454 is a potent GPIIb/IIIa antagonist that achieves maximal inhibition of platelet aggregation at lower receptor occupancy than abciximab in in vitro flow models.
No takes yet. Share an insight, caveat, or question.
Should not yet change antiplatelet practice; hypothesis-generating for lower-occupancy GPIIb/IIIa antagonists in thrombosis.
Abulencia et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: